Released On: July 31, 2019Expires On: July 31, 2020 This CE activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. Credit Available Physicians — maximum of 1.5 AMA PRA Category 1 Credits™ Nurses — 1.5 contact hours (.5 in the area of pharmacology)All other health care professionals completing …
Continue reading “Management of Non-Active Progressive MS: Current and Future Perspectives”
Release: 4/30/19Expiration: 4/30/20 Provided by the Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. This activity is supported by independent education grants from Biogen, EMD Serono, Genzyme, and Novartis. Credit Available Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™ Nurses — 1.0 contact hours (includes 1.0 pharmacology contact hours) All other …
Release Date: June 1, 2019Valid for Credit Through: June 1, 2020 Target Audience The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS). Learning Objectives 1) Describe the association, or lack thereof, of posterior fossa lesions with the presentation …
Release Date: April 1, 2019Valid for Credit Through: April 1, 2020 Target Audience The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS). Learning Objectives 1) Describe perceived barriers to physical activity participation for adolescents with pediatric-onset multiple sclerosis …
Release Date: February 28, 2019Expiration Date: February 29, 2020 Introduction This guideline was developed by a group of multiple sclerosis (MS) specialists, convened by the Consortium of Multiple Sclerosis Centers (CMSC), to serve as an educational guide and concise summary of available data and professional recommendations on the selection of disease-modifying therapy (DMT) for MS. …
Continue reading “CMSC Practical Guidelines for the Selection of Disease Modifying Therapies in MS”
Release Date: February 28, 2019Credit for this program expires February 29, 2020 Target Audience This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, and other members of the healthcare team who manage patients with multiple sclerosis (MS). Learning Objectives Upon completion of this educational activity, the …
Release Date: February 1, 2019Valid for Credit Through: February 1, 2020 Target Audience The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS). Learning Objectives 1) Identify different methods of managing fatigue in people with progressive MS and the …
Target Audience This activity is designed to meet the educational needs of physicians, nurses, and advanced practice clinicians who manage patients with multiple sclerosis (MS). Program Description MS care providers need to continually update best practices and procedures to accommodate guideline changes, research developments, and new therapeutic strategies. Among the newer guidelines are the updated …
Continue reading “New Diagnostic and MRI Criteria for MS: How Will They Change our Practice?”
Management of MS in a pediatric patient— especially in a younger child—requires a careful approach that differs in many respects from that of adults with MS. There is a need to consider the impact of treatment on the developing immune system and brain and over a longer-term disease course. This special supplement addresses the challenges …
Continue reading “Pediatric Multiple Sclerosis: Sourcebook for MS Care Professionals”
Target Audience This activity is designed to meet the educational needs of physicians, nurses, and advanced practice clinicians who manage patients with multiple sclerosis (MS). Program Description In MS management, the concepts of NEDA for “no evidence of disease activity” and MEDA for “minimal evidence of disease activity” have emerged in an attempt to define …
Continue reading “NEDA or MEDA? Defining Treatment Goals in Multiple Sclerosis”